Cover Image
Market Research Report
Product code 
1067194

Glioblastoma Multiforme Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment, By Drug Class, By End-Use, By Region; Segment Forecast, 2022 - 2030

Published: | Polaris Market Research | 110 Pages | Delivery time: 1-2 business days

Price

Back to Top
Glioblastoma Multiforme Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment, By Drug Class, By End-Use, By Region; Segment Forecast, 2022 - 2030
Published: January 1, 2022
Polaris Market Research
Content info: 110 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The global glioblastoma multiforme (GBM) treatment market size is expected to reach USD 4.82 billion by 2030 according to a new study by Polaris Market Research. The report "Glioblastoma Multiforme (GBM) Treatment Market Share, Size, Trends, Industry Analysis Report, By Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, and Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, and Others), By End-Use, By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing cases of brain tumors globally, along with glioblastoma multiforme, are the chief impelling factor that caters the market growth. Besides, the rising number of R&D activities for the effective surgery alternative, growing geriatric population, the introduction of updated techniques for diagnosis, and rapid advancements for drug delivery technologies may further act as a catalyzing factor for the global industry demand in the foreseen period.

Based on the drug class, the other segment is the dominating segment and is projected to lead the industry in the forthcoming years. It includes drugs such as corticosteroids, everolimus, and 5-aminolevulinic acid (5-ALA). These drugs are mainly prescribed to decrease the peritumoral vasogenic edema for symptomatic benefits, for lack of mineralocorticoid activity. Whereas the bevacizumab segment is expected to rise at the highest CAGR in the foreseen years. It is a targeted approved therapy for curing frequent and recent diagnosed GBM. Thereby, the continuation in a medical study for using bevacizumab with other therapies is likely to augment the adoption of the drug for the management of GBM.

The demand for novel and competent drugs is increasing because they are more likely to present effective surgery. For instance, as per the study by National Centre for Biotechnology Information (NCBI), in 2019, the patient pool of glioblastoma was increased to 3.19 per 100,000, in 2017. Accordingly, this is an alarming growth rate because the fatality of the patients is exponentially grown owing to the unavailability of the appropriate surgery. This growth requires effective therapies and drugs that help in decreasing the number of fatalities and may increase the life expectancy rate of the patients. Therefore, these are the certain factors that may create a lucrative opportunity for market growth around the world.

Market participants such as Merck & Co., Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Amgen, Inc., Arbor Pharmaceuticals, LLC, Amgen, Inc., Teva Pharmaceutical Industries Ltd., Karyopharm Therapeutics, Inc., and Pfizer Inc. are some of the key players operating in the global industry.

There are various industry vendors introducing their innovations across the global industry to reinforce their geographical footprints. For instance, in April 2021, Humanigen Inc.- a clinical-stage biopharmaceutical company, declared the positive results from its Phase 1 clinical trial of "Ifabotuzumab" in the surgery of glioblastoma multiforme. The company announces the positive results of its Humaneered antibody, Ifabotuzumab. The drug was confirmed to be very responsive, precise, and reproducible targeting the tumor and tumor microenvironment in all patients.

Polaris Market research has segmented the glioblastoma multiforme (GBM) treatment market report on the basis of treatment, drug class, end-use, and region:

Glioblastoma Multiforme (GBM) Treatment, Treatment Outlook (Revenue - USD Billion, 2018 - 2030)

Surgery

Radiation therapy

Chemotherapy

Targeted Therapy

Tumor Treating Field (TTF) Therapy

Immunotherapy

Glioblastoma Multiforme (GBM) Treatment, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Temozolomide

Bevacizumab

Lomustine

Carmustine Wafers

Others

Glioblastoma Multiforme (GBM) Treatment, End-use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Clinics

Ambulatory Surgical Centers

Glioblastoma Multiforme (GBM) Treatment, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Product Code: PM2176

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Glioblastoma Multiforme (GBM) Treatment Market Insights

  • 4.1. Glioblastoma Multiforme (GBM) Treatment - Industry Snapshot
  • 4.2. Glioblastoma Multiforme (GBM) Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
    • 4.2.2. Restraints and Challenges
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Glioblastoma Multiforme (GBM) Treatment Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Glioblastoma Multiforme (GBM) Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • 5.3. Surgery
    • 5.3.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Surgery, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Radiation therapy
    • 5.4.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Radiation therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Targeted Therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Tumor Treating Field (TTF) Therapy
    • 5.6.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Tumor Treating Field (TTF) Therapy, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Immunotherapy
    • 5.7.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Immunotherapy, by Region, 2018 - 2030 (USD Billion)

6. Global Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 6.3. Temozolomide
    • 6.3.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Temozolomide, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Bevacizumab
    • 6.4.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Bevacizumab, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Lomustine
    • 6.5.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Lomustine, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Carmustine Wafers
    • 6.6.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Carmustine Wafers, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Glioblastoma Multiforme (GBM) Treatment Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Hospitals, By Region, 2018 - 2030 (USD Billion)
  • 7.4. Clinics
    • 7.4.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Clinics, By Region, 2018 - 2030 (USD Billion)
  • 7.5. Ambulatory Surgical Centers
    • 7.5.1. Global Glioblastoma Multiforme (GBM) Treatment Market, by Ambulatory Surgical Centers, By Region, 2018 - 2030 (USD Billion)

8. Global Glioblastoma Multiforme (GBM) Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Glioblastoma Multiforme (GBM) Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Glioblastoma Multiforme (GBM) Treatment Market - North America
    • 8.3.1. North America: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.4. Glioblastoma Multiforme (GBM) Treatment Market - U.S.
      • 8.3.4.1. U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.5. Glioblastoma Multiforme (GBM) Treatment Market - Canada
      • 8.3.5.1. Canada: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 8.4. Glioblastoma Multiforme (GBM) Treatment Market - Europe
    • 8.4.1. Europe: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.4. Glioblastoma Multiforme (GBM) Treatment Market - UK
      • 8.4.4.1. UK: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.5. Glioblastoma Multiforme (GBM) Treatment Market - France
      • 8.4.5.1. France: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.6. Glioblastoma Multiforme (GBM) Treatment Market - Germany
      • 8.4.6.1. Germany: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.7. Glioblastoma Multiforme (GBM) Treatment Market - Italy
      • 8.4.7.1. Italy: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.8. Glioblastoma Multiforme (GBM) Treatment Market - Spain
      • 8.4.8.1. Spain: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.9. Glioblastoma Multiforme (GBM) Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.10. Glioblastoma Multiforme (GBM) Treatment Market - Austria
      • 8.4.10.1. Austria: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Austria.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Austria: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 8.5. Glioblastoma Multiforme (GBM) Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.4. Glioblastoma Multiforme (GBM) Treatment Market - China
      • 8.5.4.1. China: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.5. Glioblastoma Multiforme (GBM) Treatment Market - India
      • 8.5.5.1. India: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.6. Glioblastoma Multiforme (GBM) Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.7. Glioblastoma Multiforme (GBM) Treatment Market - Japan
      • 8.5.7.1. Japan: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.8. Glioblastoma Multiforme (GBM) Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.9. Glioblastoma Multiforme (GBM) Treatment Market - South Korea
      • 8.5.9.1. South Korea: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 8.6. Glioblastoma Multiforme (GBM) Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.4. Glioblastoma Multiforme (GBM) Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.5. Glioblastoma Multiforme (GBM) Treatment Market - UAE
      • 8.6.5.1. UAE: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.6. Glioblastoma Multiforme (GBM) Treatment Market - Israel
      • 8.6.6.1. Israel: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.7. Glioblastoma Multiforme (GBM) Treatment Market - South Africa
      • 8.6.7.1. South Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 8.7. Glioblastoma Multiforme (GBM) Treatment Market - Latin America
    • 8.7.1. Latin America: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.4. Glioblastoma Multiforme (GBM) Treatment Market - Mexico
      • 8.7.4.1. Mexico: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.5. Glioblastoma Multiforme (GBM) Treatment Market - Brazil
      • 8.7.5.1. Brazil: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.6. Glioblastoma Multiforme (GBM) Treatment Market - Argentina
      • 8.7.6.1. Argentina: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amgen
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Amneal Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Arbor Pharmaceuticals
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. F. Hoffmann-La Roche Ltd
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Karyopharm Therapeutics, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Merck & Co.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Pfizer Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 2 Global Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 3 Global Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 4 Glioblastoma Multiforme (GBM) Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 5 North America: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 6 North America: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 7 North America: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 8 U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 9 U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 11 Canada: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 12 Canada: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 13 Canada: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 14 Europe: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 15 Europe: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 16 Europe: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 17 UK: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 18 UK: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 19 UK: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 20 France: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 21 France: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 22 France: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 26 Italy: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 27 Italy: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 28 Italy: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 29 Spain: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 30 Spain: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 31 Spain: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 32 Netherlands: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 33 Netherlands: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 34 Netherlands: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 35 Austria: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 36 Austria: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 37 Austria: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 38 Asia Pacific: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 39 Asia Pacific: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 41 China: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 42 China: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 43 China: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 44 India: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 45 India: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 46 India: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 47 Malaysia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 48 Malaysia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 49 Malaysia: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 50 Japan: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 51 Japan: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 52 Japan: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 53 Indonesia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 54 Indonesia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 55 Indonesia: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 56 South Korea: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 57 South Korea: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 58 South Korea: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 59 Middle East & Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 60 Middle East & Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 61 Middle East & Africa: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 62 Saudi Arabia: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 63 Saudi Arabia: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 64 Saudi Arabia: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 65 UAE: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 66 UAE: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 67 UAE: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 68 Israel: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 69 Israel: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 70 Israel: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 71 South Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 72 South Africa: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 73 South Africa: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 74 Latin America: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 75 Latin America: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 76 Latin America: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 77 Mexico: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 78 Mexico: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 79 Mexico: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 80 Brazil: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 81 Brazil: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 83 Argentina: Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2018 - 2030 (USD Billion)
  • Table 84 Argentina: Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • Table 85 Argentina: Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Glioblastoma Multiforme (GBM) Treatment Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Approach

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Drug Class

Figure 7. Global Glioblastoma Multiforme (GBM) Treatment Market, by Drug Class, 2021 & 2030 (USD Billion)

Figure 8. Market by Treatment

Figure 9. Global Glioblastoma Multiforme (GBM) Treatment Market, by Treatment, 2021 & 2030 (USD Billion)

Figure 10. Market by End-Use

Figure 11. Global Glioblastoma Multiforme (GBM) Treatment Market, by End-Use, 2021 & 2030 (USD Billion)

Figure 12. Glioblastoma Multiforme (GBM) Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 13. Strategic Analysis - Glioblastoma Multiforme (GBM) Treatment Market